Gilead Sciences Files 8-K: Bylaws & Financials

TL;DR

Gilead filed an 8-K for bylaw changes and financials, no major surprises.

AI Summary

Gilead Sciences, Inc. filed an 8-K on July 30, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The filing does not contain specific financial figures or details about the amendments.

Why It Matters

This filing indicates updates to Gilead's corporate governance documents and the submission of financial information, which are standard disclosures for public companies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate governance updates and financial statements, not indicating any immediate material changes or risks.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• July 30, 2025 (date) — Date of earliest event reported
• 333 Lakeside Drive, Foster City, California 94404 (location) — Principal executive offices

FAQ

From the Filing

0000882095-25-000022.txt : 20250804 0000882095-25-000022.hdr.sgml : 20250804 20250804160716 ACCESSION NUMBER: 0000882095-25-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250730 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250804 DATE AS OF CHANGE: 20250804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 251180284 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20250730.htm FORM 8-K gild-20250730 0000882095 false 12/31 0000882095 2025-07-30 2025-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 30, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report)2 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.03      Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. On July 30, 2025 , the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”), effective as of such date, in order to: • revise the procedural and disclosure requirements for the nomination of directors and the submission of proposals for consideration at meetings of the stockholders under the advance notice provisions (other than proposals to be included in the Company’s proxy